Phase II Study of Axalimogene Filolisbac (ADXS-HPV) for Platinum-Refractory Cervical Carcinoma: an NRG Oncology/Gynecologic Oncology Group Study

OBJECTIVE: Women with persistent, recurrent, and/or metastatic cervical cancer have a poor prognosis. Even with the availability of cisplatin plus paclitaxel and bevacizumab, median overall survival (OS) is only 17.0 months, with median post-progression survival of approximately seven months. We stu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol
Main Authors: Huh, Warner K., Brady, William E., Fracasso, Paula M., Dizon, Don S., Powell, Matthew A., Monk, Bradley J., Leath, Charles A., Landrum, Lisa M., Tanner, Edward J., Crane, Erin K., Ueda, Stefanie, McHale, Michael T., Aghajanian, Carol
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7487015/
https://ncbi.nlm.nih.gov/pubmed/32641240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2020.06.493
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados